Tempus AI, Inc., a leader in artificial intelligence and precision medicine, today announced the clinical launch of the ArteraAI Prostate Test (mHSPC). The CLIA-certified and CAP-accredited prognostic ...

Tempus AI is expanding its clinical oncology offering with the launch of ArteraAI Prostate Test for metastatic hormone-sensitive prostate cancer. ・The tool combines digital pathology and genomic ...

Men with less common types of prostate cancer have worse cancer control and greater need for radiation therapy after surgery. Oncologic and functional outcomes after robot-assisted radical ...

Trading with an implied upside of 60.5% and an RSI of 34.6, Tempus AI, Inc. (NASDAQ:TEM) has emerged as a notable oversold ...

Techcyte, the developer of Fusion, the unified anatomic and clinical pathology AI platform, today announced the integration of two Aira Matrix AI algorithms into Fusion AP: AIRAProstate, an automated ...

Prostate cancer stands as a prevalent threat to men's health, ranking second in cancer-related deaths in the United States. Each year, approximately 250,000 men in the U.S. receive a prostate cancer ...

Prostate cancer is the most common cancer in men and is second most common cause of cancer deaths. Importantly, the annual rates of prostate cancer incidence continue to rise. This session will delve ...

Does a Custom Electronic Health Record Alert System Improve Physician Compliance With National Quality Measures for Palliative Bone Metastasis Radiotherapy? This approach aims to reduce delays in data ...

Pathologic concordance between prostate biopsy and radical prostatectomy improves with use of a novel robotic-assisted transperineal fusion biopsy platform. Optimization of risk stratification at ...

NEW YORK--(BUSINESS WIRE)--Paige, the global leader in AI-based diagnostic software in pathology, today announced that the U.S. Food and Drug Administration (FDA) has granted de novo marketing ...